Most shorted biotech stocks

According to Jefferies’ report, the most shorted biotech mid-cap stock (despite a slight decline in short interest) is MannKind Corporation (NASDAQ: MNKD)’s, which recently saw 44.9 percent of its float sold short, and 35 days to cover.

Second in line is Myriad Genetics, Inc. (NASDAQ: MYGN), with 42.5 percent of its float sold short, and 46 days to cover.

Theravance Inc (NASDAQ: THRX) is also very shorted, with 33.7 percent of its float sold short, up from a previous 33.0 percent. Days to cover ascend to 45.

In the smid-cap segment, Sarepta Therapeutics Inc (NASDAQ: SRPT) leads the list, with 38.0 percent of its float sold short (down from a previous 43.1 percent) and 14 days to cover.

Also among the most shorted is Enanta Pharmaceuticals Inc (NASDAQ: ENTA), with 31.9 percent of its float sold short (down from 36.4 percent) and 9 days to cover.

Finally, within small-caps, investors seem most bearish on Tokai Pharmaceuticals Inc (NASDAQ: TKAI), which recently saw short interest surge from 43.3 percent of the float, to 49.3 percent of the float.